Combined expression of the BRAF(V600E) mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence—a retrospective cohort study

BACKGROUND: Identifying the high recurrence group of patients with early-stage papillary thyroid cancer (PTC) is the greatest challenge in the management of this disease. It has been noted that B-type Rafkinase (BRAF) V600E mutation and programmed death ligand 1 (PD-L1) are associated in PTC and hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Meili, Gu, Jialei, Wang, Wendong, Wang, Kejing, Zheng, Linfeng, Feng, Jianguo, Shang, Jinbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840988/
https://www.ncbi.nlm.nih.gov/pubmed/36654945
http://dx.doi.org/10.21037/gs-22-701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840988/
https://www.ncbi.nlm.nih.gov/pubmed/36654945
http://dx.doi.org/10.21037/gs-22-701

Ejemplares similares